Semaglutide has reshaped the obesity and diabetes trial record — here is what the studies measured, read side by side with tirzepatide.

The short version

Semaglutide is a medicine you take once a week as a shot, or once a day as a pill, that copies a natural gut hormone called GLP-1 (a signal your body releases after eating that tells you you are full and helps control blood sugar). It is FDA-approved, meaning regulators reviewed large human trials and cleared it — for type 2 diabetes, for long-term weight management, to lower the risk of heart attack and stroke in certain people, and, since 2025, for a serious fatty-liver disease. In a large weight-loss trial, people lost about 15% of their body weight over roughly 16 months ^[1]. It also has real downsides — nausea is common early on, and weight tends to come back if you stop ^[1][17]. The honest comparison against a newer drug, tirzepatide, and what people actually report — including the rough parts — is on the effects page. Nothing here is medical advice or a dose to follow.

What the semaglutide literature has demonstrated

Semaglutide is a long-acting agonist of the GLP-1 receptor — a synthetic copy of the incretin hormone GLP-1 (glucagon-like peptide-1), engineered so it lasts about a week in the body instead of a couple of minutes ^[11]. That single change in durability is what turned a fragile gut hormone into a once-weekly medicine, and the trial record built on it is one of the largest in modern metabolic medicine.

The headline weight number comes from STEP 1: once-weekly subcutaneous semaglutide 2.4 mg produced a mean body-weight change of -14.9% from baseline to week 68, versus -2.4% with placebo, in adults with overweight or obesity and no diabetes ^[1]. In type 2 diabetes, the SUSTAIN program established HbA1c (a three-month average blood-sugar marker) lowering across doses ^[9].

The protection runs deeper than the scale. In SELECT (n=17,604), in people with established cardiovascular disease and obesity but no diabetes, semaglutide cut major adverse cardiovascular events by 20% versus placebo (HR 0.80; 95% CI 0.72-0.90) ^[3]. In FLOW (n=3,533), it reduced major kidney-disease events by 24% in type 2 diabetes with chronic kidney disease ^[6]. This is the Semaglutide research record in one paragraph: weight, glucose, heart, kidney.

How it works, in one read

The weight effect is mostly in the brain, not the gut. Rodent work mapped semaglutide reaching the brainstem and the hypothalamic arcuate nucleus — the small region that runs hunger and fullness — where it switches up the "I'm full" neurons and switches down the "I'm hungry" neurons, lowering food intake without dropping the body's energy burn ^[4]. People describe the result as the "food noise" going quiet.

It also does the classic incretin jobs: it nudges the pancreas to release insulin only when blood sugar is high, calms the hormone that raises blood sugar, and slows how fast the stomach empties ^[5]. That last one is why nausea shows up — and why it usually fades. The full mechanism, with citations, is on the research page.

How semaglutide compares with tirzepatide

The question readers ask most is whether the newer drug wins. The fairest answer is a single head-to-head trial. In SURMOUNT-5 (n=751), a direct comparison in adults with obesity, tirzepatide produced greater mean weight loss than semaglutide at 72 weeks: -20.2% versus -13.7%, a roughly 6.5-percentage-point advantage that was statistically significant (P<0.001) ^[7]. In diabetes, SURPASS-2 pointed the same direction for HbA1c and weight ^[8].

That does not make semaglutide a runner-up. It carries the larger cardiovascular-outcomes evidence base to date (SELECT) ^[3] and a kidney-outcomes trial (FLOW) ^[6], and it is the one with both a pill and a shot. The full side-by-side, with the numbers in a table, is the point of this site — read semaglutide vs tirzepatide.

What to watch for

An honest digest names the downsides plainly. The dominant adverse effects are gastrointestinal — nausea, vomiting, diarrhea, constipation — mostly mild-to-moderate and concentrated during the dose-escalation period ^[13]. Nausea affects roughly a third of patients in the safety literature ^[5]. Stopping the drug is followed by substantial weight regain — a mean of about 11.6 percentage points within a year in the STEP 1 extension — which is why obesity is framed as a chronic, not a curable, condition ^[17].

There are also things to flag and not overstate: a boxed warning for medullary thyroid carcinoma carried over from rodent studies (no clear human signal) ^[14], and reports of hair shedding that track rapid weight loss rather than the drug itself ^[18]. All of it, including what people report from real use, lives on the effects page.